Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesENDRA Life Sciences Inc

ENDRA Life Sciences Inc

Healthcare Diagnostics & Research
PortfolioPortfolio WatchlistWatchlist
Company price
4.73 USD -0.28 ( 5.49%)
Last update at 2026-11-06T21:00:00Z
VOLUME
1161
Market Cap
8.40M

Momentum Score

…

ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source such as radio frequency to transmit energy deep into tissue and generate ultrasonic waves to create high-contrast images for use in the treatment of non-alcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion analysis. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
4.70
Low
4.98
High
52 Week Price Range
2.96
Low
9.85
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
5.00
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.22
ROE
-152.04%
Net Debt
-0.27M
ROCE
-226.48%
Diluted EPS TTM
-6.29

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -7.03M -11.51M -10.06M -13.18M -11.23M
Net income -7.03M -11.51M -10.06M -13.20M -11.19M
Selling general administrative 3.72M 7.06M 4.70M 5.17M 4.94M
Selling and marketing expenses 0.19M 0.57M 0.82M 1.43M 1.08M
Gross profit - -0.21M -0.28M - 0.00M
Reconciled depreciation 0.16M 0.21M 0.28M 0.23M 0.22M
Ebit -7.03M -11.51M -10.06M -13.16M -11.50M
Ebitda -6.87M -11.30M -9.78M -12.92M -11.32M
Depreciation and amortization 0.16M 0.21M 0.28M 0.23M 0.18M
Operating income -5.76M -10.82M -10.52M -13.16M -11.50M
Other operating expenses 5.76M 10.82M 10.52M 13.16M 11.50M
Interest expense - - - 0.02M 0.27M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Net interest income - -7.32M - - 0.00M
Income tax expense - - -0.00M 0.02M -0.04M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 5.76M 10.82M 10.52M 13.16M 11.50M
Cost of revenue - 0.21M 0.28M - -
Total other income expense net -1.26M -0.69M 0.46M -0.02M 0.27M
Net income from continuing ops -7.03M -11.51M -11.89M -13.18M -11.23M
Net income applicable to common shares - - - -13.18M -11.35M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 3.85M 4.45M 6.75M 9.27M 12.87M
Intangible assets 2.01M - - - -
Other current assets 0.21M 0.20M 0.20M 0.99M 1.35M
Total liab 1.59M 1.89M 1.10M 2.07M 2.09M
Total stockholder equity 2.26M 2.56M 5.66M 7.20M 10.78M
Other current liab 0.24M 0.24M 0.34M 0.91M 0.62M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -110.47M -103.44M -91.93M -81.87M -68.69M
Other assets - - - 0.01M 0.01M
Cash 0.76M 3.23M 2.83M 4.89M 9.46M
Total current liabilities 0.75M 0.61M 0.90M 1.70M 1.54M
Net debt -0.27M -2.65M -2.44M -4.34M -8.78M
Short term debt 0.13M 0.10M 0.20M 0.18M 0.13M
Short long term debt - - 0.03M 0.03M -
Short long term debt total 0.49M 0.58M 0.39M 0.55M 0.68M
Other stockholder equity 112.73M 106.00M 97.58M 89.07M 79.47M
Property plant equipment - - - 0.74M 0.77M
Total current assets 0.97M 3.43M 3.03M 8.53M 12.09M
Net tangible assets - - - 7.20M 10.78M
Net receivables - - -2.62M - -
Long term debt - - - - 0.03M
Inventory - - 2.62M 2.64M 1.28M
Accounts payable 0.38M 0.27M 0.36M 0.61M 0.79M
Accumulated other comprehensive income - - 0.01M - -
Non currrent assets other 2.38M 0.37M 3.26M 0.01M 0.01M
Non current assets total 2.89M 1.02M 3.72M 0.75M 0.78M
Capital lease obligations 0.49M 0.58M 0.37M 0.52M 0.65M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.01M -0.07M -0.20M -0.04M
Change to liabilities - - - 0.11M 0.49M
Total cashflows from investing activities -3.02M -0.01M -0.02M -0.20M -0.04M
Net borrowings 0.00M -0.03M - - -
Total cash from financing activities 5.73M 7.81M 7.52M 8.40M 13.40M
Change to operating activities - - - 0.22M -1.06M
Net income -7.03M -11.51M -10.06M -13.18M -11.23M
Change in cash -2.47M 0.40M -2.06M -4.57M 2.23M
Begin period cash flow 3.23M 2.83M 4.89M 9.46M 7.23M
End period cash flow 0.76M 3.23M 2.83M 4.89M 9.46M
Total cash from operating activities -5.18M -7.40M -9.55M -12.77M -11.12M
Issuance of capital stock 5.73M 1.15M 5.83M 8.40M 10.62M
Depreciation 0.16M 0.21M 0.28M 0.23M 0.22M
Other cashflows from investing activities -3.00M 0.00M 0.01M - -
Dividends paid - 0.01M 0.00M -0.01M -0.12M
Change to inventory 0.00M 0.24M 0.14M -1.36M -0.69M
Change to account receivables - - - - -0.49M
Other cashflows from financing activities 5.73M 0.00M 1.04M 0.01M 2.91M
Change to netincome - - - 1.20M 1.15M
Capital expenditures 0.02M 0.02M 0.03M 0.20M 0.04M
Change in working capital 0.02M 0.13M -0.92M -1.03M -1.26M
Stock based compensation 0.33M 0.57M 1.00M 1.20M 1.44M
Other non cash items 1.34M 3.20M 0.16M 0.00M -0.30M
Free cash flow -5.20M -7.42M -9.58M -12.97M -11.17M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NDRA
ENDRA Life Sciences Inc		 -0.28
5.49%		 4.73 - - 1838.78 1.33 1845.91 -0.11
TMO
Thermo Fisher Scientific Inc		 17.82
2.63%		 694.76 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 3.91
1.73%		 230.25 29.09 28.01 5.67 3.20 6.00 19.09
WUXIF
WuXi AppTec Co. Ltd		 -
-%		 25.45 22.29 17.95 1.53 5.98 8.39 14.30
WUXAY
WuXi AppTec Co. Ltd		 -0.31
1.23%		 24.85 23.28 18.73 1.51 6.24 8.39 14.30

Profile*

ENDRA Life Sciences Inc

ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source such as radio frequency to transmit energy deep into tissue and generate ultrasonic waves to create high-contrast images for use in the treatment of non-alcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion analysis. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.

3600 Green Court, Ann Arbor, MI, United States, 48105-1570

734 335 0468

https://endrainc.com

9

Name Title Year Born
Mr. Francois Michelon Chairman, Pres & CEO 1966
Mr. Michael Thornton Chief Technology Officer 1968
Mr. Renaud Bertrand Maloberti Chief Commercial Officer 1969
Dr. Jonathan Behr Ph.D. Co-Founder NA
Ms. Irina Pestrikova Sr. Director of Fin. & Sec. 1987
Mr. Steve Freeman HR Leader NA
Mr. Francois Michelon Chairman, President & CEO 1966
Ms. Irina Pestrikova Senior Director of Finance & Secretary 1987
Mr. Michael Thornton Ph.D. Chief Technology Officer 1968
Mr. Steve Freeman Human Resources Leader NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…